Over 170 drugs under research to deal with the diabetes challenges; China report

14 November 2016

With the coming of the 25th“World Diabetes Day,” R&D Based Pharmaceutical Association Committee of China Association of Enterprises with Foreign Investment (RDPAC) released Faces of Innovation: Meeting the Challenge of Diabetes today in Beijing.

The report reveals the severe disease situation and heavy disease burden of diabetes in China at present, and the multiple positive significance of improving the patient's life quality and reducing social disease burden by enhancing drug innovation and improving drug accessibility.

Diabetes is the number one serious chronic disease in China. According to the statistics of International Diabetes Federation, China has the largest population who suffer from diabetes in 2015, reaching 110 million, which means that there are one-tenth of the Chinese people are suffering from diabetes and its related disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK